IPO
“The good performance we saw in the third quarter has continued to further improve.
David Roth, Chief Financial Officer of 4basebio AG, comments: “4basebio can now successfully acquire the desired number of shares in full.
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.
Funding to support GMP adenovirus manufacture for a first-in-human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Founded by UKI2S with co-investment from LifeArc & Parkwalk to advance a diabetic macular edema gene therapy and other pipeline products
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.
Corteva, Inc. reported financial results for the quarter ended December 31, 2019 and the full year 2019.
Kezar Life Sciences, Inc. has announced the pricing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share.
Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, has announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a price to the public of $17.00 per share.
PRESS RELEASES